MedTrace Logo

Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting

NCT01476280 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2011-11-22

No results posted yet for this study

Summary

Ramosetron and palonosetron are more recently developed 5-hydroxytryptamine type 3 receptor antagonists and this randomized double blind study was designed to compare efficacy of ramosetron and palonosetron to prevent postoperative nausea and vomiting. Investigator hypothesized that palonosetron would have stronger and longer lasting antiemetic effect compared with ramosetron and evaluated the patients for the first 48 hours after surgery.

Conditions

  • Postoperative Nausea and Vomiting

Interventions

DRUG

palonosetron

0.075mg immediately before induction of anesthesia

DRUG

Ramosetron

0.3mg immediately before induction of anesthesia

Sponsors & Collaborators

  • Incheon St.Mary's Hospital

    lead OTHER

Principal Investigators

  • Soo Kyoung Park · Incheon St.Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01476280 on ClinicalTrials.gov